Biogen Inc(BIIB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 AM ET (Korea 9/11 17:10)
Full metrics table
| Index | S&P 500 | P/E | 38.15 | EPS (ttm) | 5.65 | Insider Own | 0.75% | Shs Outstand | 147.7M | Perf Week | -3.25% |
| Market Cap | 31.83B | Forward P/E | 13.02 | EPS next Y | 33.29% | Insider Trans | -0.11% | Shs Float | 146.6M | Perf Month | 5.66% |
| Enterprise Value | 38.90B | PEG | 1.88 | EPS next Q | 2.03 | Inst Own | 98.6% | Short Float | 3.54% | Perf Quarter | 10.91% |
| Income | 0.83B | P/S | 3.29 | EPS this Y | -18.73% | Inst Trans | 3.12% | Short Ratio | 4.69 | Perf Half Y | 13.1% |
| Sales | 9.66B | P/B | 1.69 | EPS next 5Y | 6.93% | ROA | 2.76% | Short Interest | 5.19M | Perf YTD | 22.41% |
| Book/sh | 127.61 | P/C | 24.77 | EPS past 3/5Y | -25.04% -18.74% | ROE | 4.58% | 52W High | -4.59% ($225.80) | Perf Year | 51.06% |
| Cash/sh | 8.7 | P/FCF | 11.8 | Sales past 3/5Y | 0.35% -5.06% | ROIC | 3.16% | 52W Low | 59.12% ($135.39) | Perf 3Y | -16.82% |
| Dividend Est. | - | EV/EBITDA | 14.27 | EPS Y/Y TTM | -45.79% | Gross Margin | 64.29% | Volatility(W/M) | 2.64% 2.44% | Perf 5Y | -28.14% |
| Dividend TTM | - | EV/Sales | 4.03 | Sales Y/Y TTM | 0.53% | Oper. Margin | 19.5% | ATR (14) | 6.19 | Perf 10Y | -21.01% |
| Dividend Ex-Date | - | Quick Ratio | 1.26 | EPS Q/Q | -84.85% | Profit Margin | 8.64% | RSI (14) | 51.35 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | 2.38% | SMA20 | -0.59% ($216.71) | Beta | 0.1 | Target Price | $239.28 |
| Payout | - | Debt/Eq | 0.44 | Earnings | 2026/7/29 | SMA50 | 2.92% ($209.32) | Rel Volume | 0.84 | Prev Close | $210.73 |
| Employees | 7500 | LT Debt/Eq | 0.4 | EPS/Sales Surpr. | 22.49% 11.2% | SMA200 | 12.37% ($191.71) | Avg Volume(3M) | 1.11M | Price | $215.43 |
| IPO | 1991/9/17 | Option/Short | Yes/Yes | Trades | 17442 | Volume | 928,005 | Change | 2.23% |
Company
BIIB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 This is a global pharmaceutical company specializing in the development of treatments for multiple sclerosis, Alzheimer's disease, and rare neurological disorders. Leveraging its long-accumulated R&D capabilities and biopharmaceutical manufacturing expertise, the company has built a strong position in the field of neurological diseases.
Over the past 1 year, on the higher side
5% below its 1-year high.
BIIB makes money exceptionally well
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -18.7% this year.
Tap to view numbers
The price looks about right
Trading at 38.1 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -16.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 98.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.05%
FTXH 0.04%
IBRN 0.04%
BBH 0.04%
FBT 0.03%It ranks #4 in the industry
Based on market cap of $32B.
BIIB $32B PER 38.1
LLY $1.1T PER 38.2
JNJ $642B PER 30.9
ABBV $451B PER 72.1
FAQ
What kind of company is BIIB?
BIIB belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of BIIB?
The market cap of BIIB is approximately $31.8B, ranking 448 within its sector.
What is the P/E ratio of BIIB?
BIIB has a P/E ratio of approximately 38.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BIIB?
BIIB has recorded a 52-week high of $225.80 and a low of $135.39.
